{"id":44441,"date":"2020-04-10T17:51:45","date_gmt":"2020-04-10T08:51:45","guid":{"rendered":"https:\/\/rftcjapan.org\/uncategorized\/am-i-eligible-for-abemaciclib\/"},"modified":"2020-04-10T18:25:26","modified_gmt":"2020-04-10T09:25:26","slug":"am-i-eligible-for-abemaciclib","status":"publish","type":"post","link":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/","title":{"rendered":"Am I eligible for abemaciclib?"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row css_animation=&#8221;&#8221; row_type=&#8221;row&#8221; use_row_as_full_screen_section=&#8221;no&#8221; type=&#8221;full_width&#8221; angled_section=&#8221;no&#8221; text_align=&#8221;left&#8221; background_image_as_pattern=&#8221;without_pattern&#8221;][vc_column][vc_column_text]<\/p>\n<p style=\"text-align: right;\">PiNK 2020 Spring issue<\/p>\n<p>[\/vc_column_text][vc_empty_space height=&#8221;12px&#8221;][vc_separator type=&#8221;normal&#8221;][vc_empty_space height=&#8221;12px&#8221;][vc_column_text]<\/p>\n<h3><strong>\u3010Your Questions Answered\u3011Breast Cancer Care\u2019s experts answer your questions about breast cancer and its treatments.<\/strong><\/h3>\n<p>[\/vc_column_text][vc_empty_space][\/vc_column][\/vc_row][vc_row css_animation=&#8221;&#8221; row_type=&#8221;row&#8221; use_row_as_full_screen_section=&#8221;no&#8221; type=&#8221;full_width&#8221; angled_section=&#8221;no&#8221; text_align=&#8221;left&#8221; background_image_as_pattern=&#8221;without_pattern&#8221;][vc_column][vc_column_text]Q: I have secondary breast cancer in the lung, and have heard about a drug called abemaciclib. Can I have this?[\/vc_column_text][vc_empty_space height=&#8221;24px&#8221;][vc_column_text]<strong>A: Abemaciclib is a targeted therapy used to treat secondary breast cancer. It belongs to a group of drugs known as CDK 4\/6 inhibitors. Other drugs in the same group are palbococlib and ribociclib.These drugs can be given to people who have secondary breast cancer that that is both oestrogen receptor positive (ER+) and HER2 negative.<\/strong><\/p>\n<p><strong>Abemaciclib has been approved for use on the NHS and can be given as the first treatment for secondary breast cancer alongside an aromatase inhibitor, such as letrozole. It can also be given in combination with a drug called fulvestrant if you have had hormone therapy for secondary breast cancer in the past. Your specialist team can tell you if abemaciclib is an option in your situation.<\/strong>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row css_animation=&#8221;&#8221; row_type=&#8221;row&#8221; use_row_as_full_screen_section=&#8221;no&#8221; type=&#8221;full_width&#8221; angled_section=&#8221;no&#8221; text_align=&#8221;left&#8221; background_image_as_pattern=&#8221;without_pattern&#8221;][vc_column][vc_column_text] PiNK 2020 Spring issue [\/vc_column_text][vc_empty_space height=&#8221;12px&#8221;][vc_separator type=&#8221;normal&#8221;][vc_empty_space height=&#8221;12px&#8221;][vc_column_text] \u3010Your Questions Answered\u3011Breast Cancer&#8230;<\/p>\n","protected":false},"author":121,"featured_media":44423,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[64],"tags":[1042,697,694,1039,656,1043,725],"class_list":["post-44441","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pink-article","tag-abemaciclib-en","tag-breast-cancer-en","tag-pink-en-2","tag-q-a-en","tag-your-questions-answered","tag--en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Am I eligible for abemaciclib? - RFTC Japan<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Am I eligible for abemaciclib? - RFTC Japan\" \/>\n<meta property=\"og:description\" content=\"[vc_row css_animation=&#8221;&#8221; row_type=&#8221;row&#8221; use_row_as_full_screen_section=&#8221;no&#8221; type=&#8221;full_width&#8221; angled_section=&#8221;no&#8221; text_align=&#8221;left&#8221; background_image_as_pattern=&#8221;without_pattern&#8221;][vc_column][vc_column_text] PiNK 2020 Spring issue [\/vc_column_text][vc_empty_space height=&#8221;12px&#8221;][vc_separator type=&#8221;normal&#8221;][vc_empty_space height=&#8221;12px&#8221;][vc_column_text] \u3010Your Questions Answered\u3011Breast Cancer...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/\" \/>\n<meta property=\"og:site_name\" content=\"RFTC Japan\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-10T08:51:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-04-10T09:25:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rftcjapan.org\/wpdata\/wp-content\/uploads\/2020\/04\/PiNK-2020-SPRING-03.002-1024x576.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"576\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Marco Magnani\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Marco Magnani\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/\"},\"author\":{\"name\":\"Marco Magnani\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/#\\\/schema\\\/person\\\/5fb71c04b0dc2d2feed17e8d55cdeaa6\"},\"headline\":\"Am I eligible for abemaciclib?\",\"datePublished\":\"2020-04-10T08:51:45+00:00\",\"dateModified\":\"2020-04-10T09:25:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/\"},\"wordCount\":285,\"image\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/rftcjapan.org\\\/wpdata\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/PiNK-2020-SPRING-03.002.jpeg\",\"keywords\":[\"abemaciclib\",\"breast cancer\",\"PiNK\",\"Q &amp; A\",\"your questions answered\",\"\u30a2\u30d8\u3099\u30de\u30b7\u30af\u30ea\u30d5\u3099\",\"\u4e73\u304c\u3093\"],\"articleSection\":[\"PiNK\u8a18\u4e8b\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/\",\"url\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/\",\"name\":\"Am I eligible for abemaciclib? - RFTC Japan\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/rftcjapan.org\\\/wpdata\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/PiNK-2020-SPRING-03.002.jpeg\",\"datePublished\":\"2020-04-10T08:51:45+00:00\",\"dateModified\":\"2020-04-10T09:25:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/#\\\/schema\\\/person\\\/5fb71c04b0dc2d2feed17e8d55cdeaa6\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/#primaryimage\",\"url\":\"https:\\\/\\\/rftcjapan.org\\\/wpdata\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/PiNK-2020-SPRING-03.002.jpeg\",\"contentUrl\":\"https:\\\/\\\/rftcjapan.org\\\/wpdata\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/PiNK-2020-SPRING-03.002.jpeg\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pink-article\\\/am-i-eligible-for-abemaciclib\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Am I eligible for abemaciclib?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/\",\"name\":\"RFTC Japan\",\"description\":\"Japan&#039;s Leading Breast Cancer Foundation\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/#\\\/schema\\\/person\\\/5fb71c04b0dc2d2feed17e8d55cdeaa6\",\"name\":\"Marco Magnani\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Am I eligible for abemaciclib? - RFTC Japan","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/","og_locale":"en_US","og_type":"article","og_title":"Am I eligible for abemaciclib? - RFTC Japan","og_description":"[vc_row css_animation=&#8221;&#8221; row_type=&#8221;row&#8221; use_row_as_full_screen_section=&#8221;no&#8221; type=&#8221;full_width&#8221; angled_section=&#8221;no&#8221; text_align=&#8221;left&#8221; background_image_as_pattern=&#8221;without_pattern&#8221;][vc_column][vc_column_text] PiNK 2020 Spring issue [\/vc_column_text][vc_empty_space height=&#8221;12px&#8221;][vc_separator type=&#8221;normal&#8221;][vc_empty_space height=&#8221;12px&#8221;][vc_column_text] \u3010Your Questions Answered\u3011Breast Cancer...","og_url":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/","og_site_name":"RFTC Japan","article_published_time":"2020-04-10T08:51:45+00:00","article_modified_time":"2020-04-10T09:25:26+00:00","og_image":[{"width":1024,"height":576,"url":"https:\/\/rftcjapan.org\/wpdata\/wp-content\/uploads\/2020\/04\/PiNK-2020-SPRING-03.002-1024x576.jpeg","type":"image\/jpeg"}],"author":"Marco Magnani","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Marco Magnani","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/#article","isPartOf":{"@id":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/"},"author":{"name":"Marco Magnani","@id":"https:\/\/rftcjapan.org\/en\/#\/schema\/person\/5fb71c04b0dc2d2feed17e8d55cdeaa6"},"headline":"Am I eligible for abemaciclib?","datePublished":"2020-04-10T08:51:45+00:00","dateModified":"2020-04-10T09:25:26+00:00","mainEntityOfPage":{"@id":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/"},"wordCount":285,"image":{"@id":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/#primaryimage"},"thumbnailUrl":"https:\/\/rftcjapan.org\/wpdata\/wp-content\/uploads\/2020\/04\/PiNK-2020-SPRING-03.002.jpeg","keywords":["abemaciclib","breast cancer","PiNK","Q &amp; A","your questions answered","\u30a2\u30d8\u3099\u30de\u30b7\u30af\u30ea\u30d5\u3099","\u4e73\u304c\u3093"],"articleSection":["PiNK\u8a18\u4e8b"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/","url":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/","name":"Am I eligible for abemaciclib? - RFTC Japan","isPartOf":{"@id":"https:\/\/rftcjapan.org\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/#primaryimage"},"image":{"@id":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/#primaryimage"},"thumbnailUrl":"https:\/\/rftcjapan.org\/wpdata\/wp-content\/uploads\/2020\/04\/PiNK-2020-SPRING-03.002.jpeg","datePublished":"2020-04-10T08:51:45+00:00","dateModified":"2020-04-10T09:25:26+00:00","author":{"@id":"https:\/\/rftcjapan.org\/en\/#\/schema\/person\/5fb71c04b0dc2d2feed17e8d55cdeaa6"},"breadcrumb":{"@id":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/#primaryimage","url":"https:\/\/rftcjapan.org\/wpdata\/wp-content\/uploads\/2020\/04\/PiNK-2020-SPRING-03.002.jpeg","contentUrl":"https:\/\/rftcjapan.org\/wpdata\/wp-content\/uploads\/2020\/04\/PiNK-2020-SPRING-03.002.jpeg","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/rftcjapan.org\/en\/pink-article\/am-i-eligible-for-abemaciclib\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/rftcjapan.org\/en\/"},{"@type":"ListItem","position":2,"name":"Am I eligible for abemaciclib?"}]},{"@type":"WebSite","@id":"https:\/\/rftcjapan.org\/en\/#website","url":"https:\/\/rftcjapan.org\/en\/","name":"RFTC Japan","description":"Japan&#039;s Leading Breast Cancer Foundation","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rftcjapan.org\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/rftcjapan.org\/en\/#\/schema\/person\/5fb71c04b0dc2d2feed17e8d55cdeaa6","name":"Marco Magnani"}]}},"_links":{"self":[{"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/posts\/44441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/users\/121"}],"replies":[{"embeddable":true,"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/comments?post=44441"}],"version-history":[{"count":4,"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/posts\/44441\/revisions"}],"predecessor-version":[{"id":44458,"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/posts\/44441\/revisions\/44458"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/media\/44423"}],"wp:attachment":[{"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/media?parent=44441"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/categories?post=44441"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/tags?post=44441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}